Jobs and Careers

Senior Director, Internal Medicine Portfolio Strategy Lead

United Statesfull_timeVerifiedPosted 3 Jul 2026

💰 $358,100/yr($214,900/yr – $358,100/yr)

About the role

Use Your Power for Purpose

Everything we do, every day, is driven by an unwavering commitment to the patients, healthcare providers, and customers who depend on us. In Global Commercial Strategy (GCS), we translate science of R&D into value for patients and Pfizer — from early development through launch, growth, and LOE lifecycle. GCS serves as the strategic engine and commercial voice across the asset lifecycle — shaping asset positioning and evidence generation, leading global launches, and propelling brand performance through market and payer insights, broad efficient, and sustained access, & commercial rigor. We take pride in shaping how innovative medicines reach the people who need them most, and ensuring they are accessible, understood, valued, and appropriately utilized across every market. Our success is anchored in the following Pfizer Blueprint values: Science, Technology, Transformation and Colleagues.

What You Will Achieve

The Senior Director, IM Portfolio Strategy Lead is a senior individual contributor role within the Internal Medicine and Antivirals business, part of the Global Commercial Strategy organization, reporting to the VP, GCS, IM/AV. This role has no current direct reports and will lead through influence and senior matrixed leadership. The role is responsible for leading portfolio-level strategy, prioritization, investment decision support, and enterprise-ready strategic recommendations across the Internal Medicine and Antivirals portfolio. The colleague will bring deep commercial strategy experience, analytical rigor, scientific curiosity, and enterprise judgment to help shape portfolio choices, pipeline opportunities, lifecycle priorities, and external innovation strategy.

The Internal Medicine and Antivirals portfolio represents significant strategic value to realizing Pfizer's vision to achieve leadership via breakthroughs in prioritized diseases to generate highly differentiated, multi-indication mega-blockbusters. Today, the portfolio delivers more than $11B globally.

This colleague will serve as a senior portfolio strategy partner to the VP, GCS, IM/AV, DALs, and cross-functional leaders, helping translate scientific, clinical, market, access, competitive, and business insights into clear portfolio priorities and disciplined trade-off decisions. The role will support strategic planning across near-, mid-, and long-term horizons and ensure that portfolio recommendations are grounded in patient need, scientific opportunity, market potential, access dynamics, and enterprise value.

This role requires an experienced commercial strategist who can operate across ambiguity, influence senior stakeholders without direct authority, and connect work across disease areas, assets, lifecycle opportunities, and external innovation. The Senior Director will help establish repeatable approaches, decision frameworks, and AI-enabled ways of working that improve the quality, consistency, and speed of portfolio strategy development across Internal Medicine and Antivirals.

Responsibilities:

Portfolio Strategy and Long-Range Planning:

Lead development of long-range commercial and portfolio strategy across the Internal Medicine and Antivirals portfolio, spanning pipeline assets, lifecycle opportunities, external innovation, and emerging disease-area opportunities.

Establish integrated near-, mid-, and long-term views of portfolio opportunities, risks, and investment priorities to inform enterprise decision-making.

Synthesize scientific, clinical, commercial, access, competitive, financial, and patient insights to identify priority opportunities and strategic trade-offs.

Monitor shifts in the scientific, competitive, and market landscape to identify emerging trends, discontinuities, and implications for future Internal Medicine and Antivirals strategy.